Connect with us

Government

Top Reopening Stocks To Buy Now? 3 Hot Stocks To Watch

While meme stocks may be hot, investors might not want to overlook these trending reopening trades now.
The post Top Reopening Stocks To Buy Now? 3 Hot Stocks To Watch appeared first on Stock Market News, Quotes, Charts and Financial Information | St…

Published

on

Could These Be The Best Reopening Stocks To Invest In This Week?

When it comes to the best stocks to invest in 2021, some would argue that reopening stocks would fit the bill now. Why? In the stock market, this industry comprises companies that are well-positioned to flourish as the economy reopens. In a broader sense, these are organizations whose core businesses were either heavily impacted or entirely halted at the onslaught of the pandemic. Now, thanks to increasingly available vaccines, parts of the world are heading towards the tail-end of the pandemic. On top of businesses reopening, consumers would also be looking to indulge in post-pandemic means of entertainment.

Now, one notable area would be the travel industry. From airline stocks to cruise line stocks and vacation rental companies, many stand to benefit from the return of travel. Even now, we can see that this tailwind seems likely to persist moving forward. Yesterday, Boeing (NYSE: BA) revealed that its orders continue to outpace cancellations for a fourth consecutive month in May. This would be thanks to airline operators such as Southwest Airlines (NYSE: LUV) increasing their orders. Moreover, the U.S. Centers for Disease Control and Prevention (CDC) eased travel recommendations on 110 countries earlier this week.

Aside from the tourism market, there are plenty of other points of entry into the reopening trade for investors now. On one hand, you have brick-and-mortar retail players like American Eagle Outfitters (NYSE: AEO) thriving as consumers return to malls. On the other hand, live entertainment company Live Nation Entertainment (NYSE: LYV) would be busy with festivals making a comeback. By and large, the reopening trade appears to be firing on all cylinders at the moment. As such, I could see investors eyeing the top reopening stocks in the stock market today. Should you fall into the same boat, here are three making waves now.

Top Reopening Stocks To Watch In June 2021

Target Corporation

Target is a retail corporation and is also a component of the S&P 500. The company has stores in all 50 U.S. states and claims that 75% of the U.S. population lives within 10 miles of a Target store. This comes to over 1,900 stores and 44 distribution centers. Impressively, it also has 48 owned brands that are unique to Target. TGT stock currently trades at $233.10 as of 12:40 p.m. ET and is up by over 30% year-to-date. Today, the company announced that it has increased its quarterly dividend by 32% to $0.90 per share.

Last month, the company reported strong first-quarter financials. Firstly, comparable sales increased by 18% year-over-year. Secondly, its digital comparable sales grew by 50% in that same period. It also reported first-quarter GAAP earnings per share of $4.17, up by a whopping 643% year-over-year. Importantly, the company also saw market-share gains of more than $1 billion in the first quarter, on top of $1 billion in share gains a year ago.

In March, the company stated that it had been continuing to build on the momentum and announced its 2021 strategic investments. Specifically, it plans to invest approximately $4 billion annually during the next few years to continue scaling capabilities across its retail platform. It will accelerate new store openings and store remodels, enhance fulfillment services and strengthen its supply chain as it provides guests with a safe, easy, and convenient shopping experience. For these reasons, will you consider buying TGT stock?

Source: TD Ameritrade TOS

Read More

Airbnb Inc.

Airbnb is a reopening stock that operates an online marketplace for hosts to rent out homestays and tourism activities. The company has over 4 million hosts who have welcomed more than 900 million guest arrivals in almost every country across the globe. ABNB stock currently trades at $147.89 as of 12:40 p.m. ET. On Monday, the company announced an exciting piece of news, much to investor delight.

In detail, the company launched The Great Rebalance of European Travel, a series of commitments to work with communities in Europe to help rebalance tourism following the pandemic. Notably, Airbnb plans to support the regulation of short-term rentals. It aims to collaborate with governments to redistribute tourism and help prevent the return of overtourism, where too much tourism is concentrated in too few places.

Last month, the company introduced the Airbnb 2021 Release which includes over 100 innovations and upgrades across its entire service in light of the economy reopening all over the world. This includes adding features to give guests even more flexibility when planning their travel and to make it simpler for anyone to become a host. The new features would also give better support for hosts and guests to meet a new era in travel. This in turn could increase its host and user count in the long run given how many people are eager for travel. Given all of this, is ABNB stock a top reopening stock to consider buying?

reopening stocks (ABNB stock)
Source: TD Ameritrade TOS

[Read More] 4 Artificial Intelligence Stocks To Watch Right Now

Abercrombie & Fitch Co.

Abercrombie & Fitch (ANF) is a lifestyle retailer that focuses on casual wear. It sells its apparel and accessories for men, women, and kids through its five brands. Among the five, it has three other offshoot brands: Abercrombie Kids, Hollister Co., and Gilly Hicks. Today, the company boasts approximately 730 stores across the globe and also a strong e-commerce presence across its brands. ANF stock currently trades at $41.68 as of 12:41 p.m. ET and has been up by over 200% in the last year.

Today, the company received a stock rating upgrade from Jefferies Financial Group. Diving in, the equities researchers at Jefferies upgraded ANF stock from a hold rating to a buy rating in a report it released today. It also set a price objective of $57 on the apparel retailer’s stock. This has been attributed to ongoing benefits from years of brand elevation efforts as well as an increase in profit margins.

Late last month, the company also reported impressive first-quarter financials. In it, ANF says it has achieved its best first-quarter operating income since 2008. Net sales for the quarter were $781 million, up by 61% compared to last year. Digital net sales increased by 45% to $403 million, reflecting robust growth. ANF also posted a net income per diluted share of $0.64. With such impressive financials, would you say that ANF stock is worth adding to your portfolio?

top reopening stocks to buy now (ANF stock)
Source: TD Ameritrade TOS

The post Top Reopening Stocks To Buy Now? 3 Hot Stocks To Watch appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Spread & Containment

AstraZeneca antibody cocktail fails to prevent Covid-19 symptoms in large trial

AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

Published

on

Astra antibody cocktail fails to prevent COVID-19 symptoms in large trial

(Reuters; )

June 15 (Reuters) – AstraZeneca (AZN.L) said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.

The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.

Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

FILE PHOTO: A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19, better known as the coronavirus linked to the Wuhan outbreak, shared with Reuters on February 18, 2020. NEXU Science Communication/via REUTERS

“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” AstraZeneca Executive Vice President Mene Pangalos said in a statement.

The company is banking on further studies to revive the product’s fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.

The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

TARGETED ALTERNATIVES

AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.

Similar therapies developed by rivals Regeneron (REGN.O) and Eli Lilly (LLY.N) have been approved by U.S. regulators for treating unhospitalised COVID patients.

European regulators have also authorised Regeneron’s therapy and are reviewing those developed by partners GlaxoSmithKline (GSK.L) and Vir Biotechnology (VIR.O) as well as by Lilly and Celltrion (068270.KS).

Regeneron is also seeking U.S. authorisation for its therapy as a preventative treatment.

But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to COVID-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza (LONN.S) was contracted to produce AZD7442.

Shares in the company were largely unchanged on the London Stock Exchange.

The full results will be submitted for publication in a peer-reviewed medical journal, the company said.

Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-its-antibody-treatment-failed-in-preventing-covid-19-exposed-2021-06-15

 

Read More

Continue Reading

Government

Former FDA Head Takes on Exec Role at Flagship’s Preemptive Health Initiative

Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration under former President Donald Trump, took on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm…

Published

on

Former FDA Head Takes on Exec Role at Flagship’s Preemptive Health Initiative

 

Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration (FDA) under former President Donald Trump, has taken on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm that incubates and curates biopharma companies.

First announced Monday, Flagship’s Preemptive Medicine and Health Security initiative aimed at developing products that can help people before they get sick. This division will focus on infectious disease threats and pursue bold treatments for existing diseases, including cancer, obesity, and neurodegeneration. 

In a brief statement, Hahn, who served as commissioner from December 2019 until January 2021, said the importance of investing in innovation and preemptive medications has never been more apparent. 

“In my career I have been a doctor and a researcher foremost and it is an honor to join Flagship Pioneering in its efforts to prioritize innovation, particularly in its Preemptive Medicine and Health Security Initiative. The more we can embrace a “what if …” approach the better we can support and protect the health and well-being of people here in the U.S. and around the world,” Hahn said in a statement. 

During his time at the FDA, Hahn was at the forefront of the government’s effort to battle the COVID-19 pandemic. His office oversaw the regulatory authorization of antivirals, antibody therapeutics and vaccines, as well as diagnostics and other tools to battle the novel coronavirus. 

Kevin Dietsch-Pool/Getty Images

Hahn bore the brunt of verbal barbs aimed at the FDA by the former president for not rushing to authorize a vaccine for COVID-19 ahead of the November 2020 election. The second vaccine authorized by the FDA for COVID-19 was developed by Moderna, a Flagship company. 

Prior to his confirmation as FDA Commissioner, Hahn, a well-respected oncologist, served as chief medical executive of the vaunted The University of Texas MD Anderson Cancer Center. Hahn was named deputy president and chief operating officer in 2017. In that role, he was responsible for the day-to-day operations of the cancer center, which includes managing more than 21,000 employees and a $5.2 billion operating budget. He was promoted to that position two years after joining MD Anderson as division head, department chair and professor of Radiation Oncology. Prior to MD Anderson, Hahn served as head of the radiation oncology department at the University of Pennsylvania’s Perelman School of Medicine.

Flagship Founder and Chief Executive Officer Noubar Afeyan said the COVID-19 pandemic that shut down economies and caused the deaths of more than 3.8 million people across the world was an important reminder that health security is a top global priority. In addition, the ongoing pandemic brings into “stark focus” the importance of preemptive medications. 

Hahn, who helmed the FDA for three years and before that served as chief medical executive at The University of Texas MD Anderson Cancer Center, has extensive experience overseeing clinical and administrative programs. Afeyan said the new division would benefit from Hahn’s experience as FDA Commissioner and help steer the Preemptive Medicine and Health Security initiative as it explores Flagship’s “growing number of explorations and companies in this emerging field.”

It is not unusual for former FDA heads to take prominent roles with companies. For example, former FDA Commissioner Scott Gottlieb, Trump’s first FDA Commissioner, took a position on the Pfizer Board of Directors weeks after departing his government role. He has also taken positions on other boards since then, including Aetion, FasterCures and Illumina.

 

BioSpace source:

https://www.biospace.com/article/former-fda-head-stephen-hahn-takes-cmo-role-at-flagship-pioneering-preemptive-health-initiative-

 

Read More

Continue Reading

Government

Five U.S. states had coronavirus infections even before first reported cases – study

At least seven people in five U.S. states were infected with the novel coronavirus weeks before those states reported their first cases, a new government study showed.

Published

on

Five U.S. states had coronavirus infections even before first reported cases – study

(Reuters) – At least seven people in five U.S. states were infected with the novel coronavirus weeks before those states reported their first cases, a new government study showed.

Participants who reported antibodies against SARS-CoV-2 were likely exposed to the virus at least several weeks before their sample was taken, as the antibodies do not appear until about two weeks after a person has been infected, the researchers said.

The latest results build on findings from a Centers for Disease Control and Prevention study that suggested the novel coronavirus may have been circulating in the United States last December, well before the first COVID-19 case was diagnosed on Jan. 19, 2020.

A protective face mask lays, as the global outbreak of the coronavirus disease (COVID-19) continues, beside leaves at the lakefront in Chicago, Illinois, U.S., December 6, 2020. REUTERS/Shannon/File Photo

The positive samples came from Illinois, Massachusetts, Mississippi, Pennsylvania and Wisconsin, and were part of a study of more than 24,000 blood samples taken for a National Institutes of Health research program between Jan. 2 and March 18, 2020.

Samples from participants in Illinois were collected on Jan. 7 and Massachusetts on Jan. 8, suggesting that the virus was present in those states as early as late December.

“This study allows us to uncover more information about the beginning of the U.S. epidemic,” said Josh Denny, one of the study authors.

The findings were published in the journal Clinical Infectious Diseases.

Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D’Silva

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/five-us-states-had-coronavirus-infections-even-before-first-reported-cases-study-2021-06-15

 

Read More

Continue Reading

Trending